Nothing new on Rafaelin the last three months. We read the news on it every day, write up anything that matters once a week, and tell you sooner if something can't wait. A quiet stretch is normal and is not a signal by itself.
Rafael analyst price targets
No Wall Street analysts cover Rafaelyet. That’s common for smaller companies. We’ll show their price targets here once coverage begins.
Rafael earnings
Earnings history
EstimateBeatMiss
Rafael’s next earnings date
Next earnings
OCT
28
Metrics we are tracking
Metric
Expectations
Status
Phase 3 Clinical Data
Positive topline results for the TransportNPC trial in Q3 2026
Last patient visit completed June 10, 2026
Cash Runway
Maintaining at least $15 million in cash through the NDA filing
$30.5 million as of April 30, 2026
NDA Submission Timeline
Filing the New Drug Application before the end of calendar 2026
Expected second half of calendar 2026
R&D Spend Efficiency
Keeping quarterly R&D expenses below $6 million post-trial
$4.9 million in Q3 FY2026
Stay on top of Rafael
Follow Rafael to get the latest and most important updates.